Long-term evaluation of tamsulosin in benign prostatic hyperplasia: Placebo-controlled, double-blind extension of phase III trial

Urology

Volumn 51, Issue 6, 1998, Pages 901-906

  Lepor, Herbert ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; TAMSULOSIN;

ADULT; ALPHA ADRENERGIC RECEPTOR BLOCKING; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HUMAN; HUMAN TISSUE; INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RHINITIS; SCORING SYSTEM; TOOTH DISEASE; URINE FLOW RATE;

ADRENERGIC ALPHA-ANTAGONISTS; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; REMISSION INDUCTION; SULFONAMIDES; TIME FACTORS;

EID: 0032101597     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00127-7     Document Type: Article

References (11)

1. Lepor H, for the Tamsulosin Investigator Group: Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 51: 892-900, 1998.
2. Chapple C.R. Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia rationale and clinical experience . Eur Urol. 29:1996;129-144.
3. Ford A.P., Williams T.J., Blue D.R., et al. Alpha 1-adrenoceptor classification sharpening Occam's razor . Trends Pharmacol Sci. 15:1994;167-170.
4. 1C subtype. Mol Pharmacol. 45:1994;703-708.
5. Lepor H., Tang R., Kobayashi S., et al. Localization of the α1A-adrenoceptor in the human prostate. J Urol. 154:1995;2096-2099.
6. Foglar R., Shibata K., Horie K., et al. Use of recombinant alpha 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol. 288:1995;201-207.
7. 1A-adrenoceptor antagonist a meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH) . Eur Urol. 29:1996;155-167.
8. 1A-adrenoceptor antagonist analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH) . Eur Urol. 29:1996;145-154.
9. 1C-adrenoceptor antagonist a randomized, controlled trial in patients with benign prostatic "obstruction" (symptomatic BPH) . Br J Urol. 76:1995;325-336.
10. Lowe F.C. Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia pharmacodynamic effect . Clin Ther. 19:1997;730-742.
11. Boyle P. Epidemiology of benign prostatic hyperplasia risk factors and concomitance with hypertension . Br J Clin Pract. 74:(suppl):1994;18-22.